Skip to content
value.today

BeyondSpring Inc.: peers

Change the peers

BeyondSpring Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Reviva Pharmaceuticals Holdings, Inc., Zivo Bioscience Inc., Cell Source, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

BeyondSpring Inc., Actuate Therapeutics, Inc., Context Therapeutics Inc., Reviva Pharmaceuticals Holdings, Inc., Aytu Bioscience, Zivo Bioscience Inc., Cell Source, Inc., Karyopharm Therapeutics Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureBeyondSpring Inc.base
BYSI · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Actuate Therapeutics, Inc.
ACTU · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Context Therapeutics Inc.
CNTX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Reviva Pharmaceuticals Holdings, Inc.
RVPH · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Aytu Bioscience
AYTU · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Zivo Bioscience Inc.
ZIVO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Cell Source, Inc.
CLCS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Karyopharm Therapeutics Inc.
KPTI · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$22 MOct 30, 2026 · Market data3rd of 8$22 MOct 30, 2026 · Market data1st of 8$22 MOct 27, 2026 · Market data2nd of 8$21 Mlast known, Mar 8, 2026 · Market dataLast known value: no current one4th of 8$21 MOct 26, 2026 · Market data5th of 8$20 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one6th of 8$20 Mlast known, Dec 25, 2022 · Market dataLast known value: no current one6th of 8$20 MOct 30, 2026 · Market data8th of 8$21 M8 ranked
Revenue (Better neither way: ranked highest first)————————$58 MFY2026 · SEC2nd of 3$0 MFY2024 · SEC3rd of 3——$146 MFY2025 · SEC1st of 3$58 M3 ranked
Net income (Higher is better)$-1 MFY2025 · SEC1st of 8$-22 MFY2025 · SEC6th of 8$-36 MFY2025 · SEC7th of 8$-20 MFY2025 · SEC5th of 8$-14 MFY2026 · SEC4th of 8$-13 MFY2024 · SEC3rd of 8$-5 MFY2024 · SEC2nd of 8$-196 MFY2025 · SEC8th of 8$-17 M8 ranked
Employees (Better neither way: ranked highest first)——12December 31, 2025 · Profile2nd of 2——————————442As on 2021 · Profile1st of 22272 ranked
Growth
Revenue growth (Higher is better)————————————————-13.3%FY2026 · SEC2nd of 213th9th————————+0.6%FY2025 · SEC1st of 227th31st-6.3%2 ranked
Revenue growth, 3 years a year (Higher is better)————————————————-18.8%FY2026 · SEC2nd of 28th4th————————-2.4%FY2025 · SEC1st of 221st25th-10.6%2 ranked
Margins and returns
Gross margin (Higher is better)————————————————64.0%FY2026 · SEConly one with it58th78th————————————64.0%—
Operating margin (Higher is better)————————————————-14.4%FY2026 · SEC1st of 244th24th————————-62.1%FY2025 · SEC2nd of 229th14th-38.3%2 ranked
Net margin (Higher is better)————————————————-24.8%FY2026 · SEC1st of 240th20th————————-134.2%FY2025 · SEC2nd of 220th8th-79.5%2 ranked
Free cash flow margin (Higher is better)————————————————5.7%FY2026 · SEC1st of 263rd56th————————-51.6%FY2025 · SEC2nd of 227th12th-23.0%2 ranked
Return on equity (Higher is better)————-554.4%FY2025 · SEC4th of 42nd1st-46.4%FY2025 · SEC1st of 445th19th-419.9%FY2025 · SEC3rd of 42nd1st-52.5%FY2026 · SEC2nd of 442nd18th————————————-236.2%4 ranked
Valuation
Price to sales (Better neither way: ranked highest first)————————————————0.4×price Oct 26, 2026 · Market data1st of 26th11th————————0.1×price Oct 30, 2026 · Market data2nd of 21st4th0.3×2 ranked
Price to book (Better neither way: ranked highest first)————2.8×price Oct 30, 2026 · Market data1st of 347th59th0.4×price Oct 27, 2026 · Market data3rd of 33rd4th————0.6×price Oct 26, 2026 · Market data2nd of 39th9th————————————0.6×3 ranked
Free cash flow yield (Higher is better)-92.1%price Oct 30, 2026 · Market data2nd of 39th3rd————-119.8%price Oct 27, 2026 · Market data3rd of 36th2nd————15.7%price Oct 26, 2026 · Market data1st of 397th94th————————————-92.1%3 ranked
Financial strength
Debt to equity (Lower is better)————————————————0.3×FY2026 · SEConly one with it36th27th————————————0.3×—
Interest cover (Higher is better)————————————————-4.4×FY2026 · SEConly one with it57th31st————————————-4.4×—
Piotroski F-score (Higher is better)————————4 of 9FY2026 · SEConly one with it——————4.0 of 9—
Scorecard
Scorecard (Higher is better)2 of 9FY2025 · Scorecard3rd of 82 of 9FY2025 · Scorecard3rd of 82 of 12FY2025 · Scorecard5th of 81 of 6FY2025 · Scorecard5th of 89 of 21FY2026 · Scorecard1st of 80 of 7FY2024 · Scorecard7th of 80 of 6FY2024 · Scorecard7th of 85 of 18FY2025 · Scorecard2nd of 819% passed8 ranked
Valuation checks (Higher is better)0 of 4FY2025 · Scorecard5th of 51 of 3FY2025 · Scorecard2nd of 51 of 4FY2025 · Scorecard3rd of 5——3 of 5FY2026 · Scorecard1st of 5————1 of 4FY2025 · Scorecard3rd of 525% passed5 ranked
Growth checks (Higher is better)1 of 1FY2025 · Scorecard1st of 80 of 1FY2025 · Scorecard4th of 80 of 2FY2025 · Scorecard4th of 80 of 1FY2025 · Scorecard4th of 81 of 5FY2026 · Scorecard3rd of 80 of 2FY2024 · Scorecard4th of 80 of 2FY2024 · Scorecard4th of 82 of 6FY2025 · Scorecard2nd of 80% passed8 ranked
Profitability checks (Higher is better)0 of 2FY2025 · Scorecard3rd of 80 of 2FY2025 · Scorecard3rd of 80 of 3FY2025 · Scorecard3rd of 80 of 3FY2025 · Scorecard3rd of 82 of 5FY2026 · Scorecard1st of 80 of 2FY2024 · Scorecard3rd of 80 of 2FY2024 · Scorecard3rd of 81 of 4FY2025 · Scorecard2nd of 80% passed8 ranked
Financial health checks (Higher is better)1 of 2FY2025 · Scorecard1st of 81 of 2FY2025 · Scorecard1st of 81 of 2FY2025 · Scorecard1st of 81 of 2FY2025 · Scorecard1st of 83 of 6FY2026 · Scorecard1st of 80 of 2FY2024 · Scorecard7th of 80 of 1FY2024 · Scorecard7th of 81 of 3FY2025 · Scorecard6th of 850% passed8 ranked
Shareholder returns checks (Higher is better)——0 of 1FY2025 · Scorecard1st of 50 of 1FY2025 · Scorecard1st of 5————0 of 1FY2024 · Scorecard1st of 50 of 1FY2024 · Scorecard1st of 50 of 1FY2025 · Scorecard1st of 50% passed5 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)13.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 755.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 763.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 70.1%2026-Q2 · 13F7th of 734.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 70.1%2025-Q4 · 13F6th of 7——76.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 734.2%7 ranked
Institutions holding (Better neither way: ranked highest first)192026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7402026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7872026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 752026-Q2 · 13F6th of 7362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 732025-Q4 · 13F7th of 7——922026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7367 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)+0.2 pp2026-Q2 against 2026-Q1 · 13F3rd of 7-2.2 pp2026-Q2 against 2026-Q1 · 13F5th of 7-17.8 pp2026-Q2 against 2026-Q1 · 13F6th of 7-22.7 pp2026-Q2 against 2026-Q1 · 13F7th of 7+8.9 pp2026-Q2 against 2026-Q1 · 13F2nd of 7+0.0 pp2025-Q4 against 2025-Q3 · 13F4th of 7——+16.5 pp2026-Q2 against 2026-Q1 · 13F1st of 7+0.0 pp7 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = BeyondSpring Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Actuate Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Context Therapeutics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Reviva Pharmaceuticals Holdings, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Aytu Bioscience: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Zivo Bioscience Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Cell Source, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Karyopharm Therapeutics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
BeyondSpring Inc.———
Actuate Therapeutics, Inc.———
Context Therapeutics Inc.———
Reviva Pharmaceuticals Holdings, Inc.———
Aytu Bioscience-14.4%FY2026
44th percentile in Healthcaremedian -7.7%, 674 companies
24th percentile in USAmedian 3.5%, 2,594 companies
Zivo Bioscience Inc.———
Cell Source, Inc.———
Karyopharm Therapeutics Inc.-62.1%FY2025
29th percentile in Healthcaremedian -7.7%, 674 companies
14th percentile in USAmedian 3.5%, 2,594 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$52 M$105 M$157 M$210 M20112013201520172019202120232025BeyondSpring Inc. $1 MAytu Bioscience $58 MZivo Bioscience Inc. $0 MKaryopharm Therapeutics Inc. $146 M

Rank in the group

1st2nd3rd201420152016201720182019202020212022202320242025BeyondSpring Inc.: 3rd of 3 in 2021BeyondSpring Inc.: 3rd of 3 in 2022BeyondSpring Inc.Aytu Bioscience: 2nd of 2 in 2014Aytu Bioscience: 1st of 2 in 2015Aytu Bioscience: 1st of 2 in 2016Aytu Bioscience: 1st of 2 in 2017Aytu Bioscience: 2nd of 2 in 2018Aytu Bioscience: 2nd of 2 in 2019Aytu Bioscience: 2nd of 3 in 2020Aytu Bioscience: 2nd of 3 in 2021Aytu Bioscience: 2nd of 3 in 2022Aytu Bioscience: 2nd of 3 in 2023Aytu Bioscience: 2nd of 3 in 2024Aytu Bioscience: 2nd of 2 in 2025Aytu BioscienceZivo Bioscience Inc.: 3rd of 3 in 2020Zivo Bioscience Inc.: 3rd of 3 in 2023Zivo Bioscience Inc.: 3rd of 3 in 2024Zivo Bioscience Inc.Karyopharm Therapeutics Inc.: 1st of 2 in 2014Karyopharm Therapeutics Inc.: 2nd of 2 in 2015Karyopharm Therapeutics Inc.: 2nd of 2 in 2016Karyopharm Therapeutics Inc.: 2nd of 2 in 2017Karyopharm Therapeutics Inc.: 1st of 2 in 2018Karyopharm Therapeutics Inc.: 1st of 2 in 2019Karyopharm Therapeutics Inc.: 1st of 3 in 2020Karyopharm Therapeutics Inc.: 1st of 3 in 2021Karyopharm Therapeutics Inc.: 1st of 3 in 2022Karyopharm Therapeutics Inc.: 1st of 3 in 2023Karyopharm Therapeutics Inc.: 1st of 3 in 2024Karyopharm Therapeutics Inc.: 1st of 2 in 2025Karyopharm Therapeutics In
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearBeyondSpring Inc.Actuate Therapeutics, Inc.Context Therapeutics Inc.Reviva Pharmaceuticals Holdings, Inc.Aytu BioscienceZivo Bioscience Inc.Cell Source, Inc.Karyopharm Therapeutics Inc.
2026————$58 MSEC———
2025————$66 MSEC2nd——$146 MSEC1st
2024————$65 MSEC2nd$0 MSEC3rd—$145 MSEC1st
2023————$107 MSEC2nd$0 MSEC3rd—$146 MSEC1st
2022$1 MSEC3rd———$97 MSEC2nd——$157 MSEC1st
2021$1 MSEC3rd———$66 MSEC2nd——$210 MSEC1st
2020————$28 MSEC2nd$0 MSEC3rd—$108 MSEC1st
2019————$7 MSEC2nd——$41 MSEC1st
2018————$4 MSEC2nd——$30 MSEC1st
2017————$3 MSEC1st——$2 MSEC2nd
2016————$3 MSEC1st——$0 MSEC2nd
2015————$0 MSEC1st——$0 MSEC2nd

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of BeyondSpring Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Actuate Therapeutics, Inc.ACTU · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $22 M market cap against $22 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $22 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Context Therapeutics Inc.CNTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $22 M market cap against $22 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $22 M (Oct 27, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Reviva Pharmaceuticals Holdings, Inc.RVPH · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $21 M market cap against $22 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $21 M (last known, Mar 8, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Aytu BioscienceAYTU · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $21 M market cap against $22 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $21 M (Oct 26, 2026) · revenue $58 M (year to June 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Zivo Bioscience Inc.ZIVO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $22 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2024)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Cell Source, Inc.CLCS · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $22 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (last known, Dec 25, 2022)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Karyopharm Therapeutics Inc.KPTI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $22 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (Oct 30, 2026) · revenue $146 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Seres Therapeutics, Inc.MCRB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $22 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (Oct 30, 2026) · revenue $1 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Black Hawk Acquisition CorporationBKHA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $22 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (Oct 30, 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • PMGC Holdings Inc.ELAB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $24 M market cap against $22 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $24 M (Oct 14, 2026) · revenue $1 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Longeveron Inc.LGVN · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $24 M market cap against $22 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $24 M (Aug 1, 2026) · revenue $1 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • MIRA Pharmaceuticals, Inc.MIRA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $24 M market cap against $22 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $24 M (Oct 30, 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.